PDGFRB and central nervous system cancer: Imatinib, also known as imatinib mesylate, STI571, CGP57148B, and Gleevec, disrupts PDGF/PDGFR autocrine and paracrine loops and interferes with the growth of glioma cell lines in vitro and in vivo [111].